Torthaí cuardaigh - Allison Berger

  • 1 - 19 toradh as 19 á dtaispeáint
Beachtaigh na torthaí
  1. 1
    Gα<sub>s</sub>-Induced Neurodegeneration in<i>Caenorhabditis elegans</i>

    Gα<sub>s</sub>-Induced Neurodegeneration in<i>Caenorhabditis elegans</i> de réir Allison Berger, Anne C. Hart, Joshua M. Kaplan

    Foilsithe / Cruthaithe 1998
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  2. 2
    Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating agents

    Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating agents de réir Cody Paiva, J. Claire Godbersen, Allison Berger, Jennifer R. Brown, Alexey V. Danilov

    Foilsithe / Cruthaithe 2015
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  3. 3
    The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation

    The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation de réir Akito Nakamura, Stephen Grossman, Keli Song, Kristina Xega, Yuhong Zhang, Donna Cvet, Allison Berger, Gary Shapiro, Dennis Huszar

    Foilsithe / Cruthaithe 2022
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  4. 4
    Targeting ubiquitin-activating enzyme induces ER stress–mediated apoptosis in B-cell lymphoma cells

    Targeting ubiquitin-activating enzyme induces ER stress–mediated apoptosis in B-cell lymphoma cells de réir Scott Best, Taylor Hashiguchi, Adam S. Kittai, Nur Bruss, Cody Paiva, Craig Okada, Tingting Liu, Allison Berger, Alexey V. Danilov

    Foilsithe / Cruthaithe 2019
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  5. 5
    Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells

    Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells de réir Ze Tian, Jian-Jun Zhao, Yu‐Tzu Tai, Samirkumar B. Amin, Yiguo Hu, Allison Berger, Paul G. Richardson, Dharminder Chauhan, Kenneth C. Anderson

    Foilsithe / Cruthaithe 2012
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  6. 6
    Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells

    Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells de réir Scott Best, Vi Lam, Tingting Liu, Nur Bruss, Adam S. Kittai, Olga V. Danilova, Susan Murray, Allison Berger, Nathan D. Pennock, Evan Lind, Alexey V. Danilov

    Foilsithe / Cruthaithe 2020
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  7. 7
    Overcoming Platinum Resistance in Preclinical Models of Ovarian Cancer Using the Neddylation Inhibitor MLN4924

    Overcoming Platinum Resistance in Preclinical Models of Ovarian Cancer Using the Neddylation Inhibitor MLN4924 de réir Amir A. Jazaeri, Etsuko Shibata, Jong-Hoon Park, Jennifer Bryant, Mark R. Conaway, Susan C. Modesitt, Peter G. Smith, Michael A. Milhollen, Allison Berger, Anindya Dutta

    Foilsithe / Cruthaithe 2013
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  8. 8
    Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer

    Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer de réir Steffan T. Nawrocki, Kevin R. Kelly, Peter G. Smith, Claudia M. Espitia, Anthony Possemato, Sean A. Beausoleil, Michael A. Milhollen, Stephen J. Blakemore, Michaël Thomas, Allison Berger, Jennifer S. Carew

    Foilsithe / Cruthaithe 2013
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  9. 9
    The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR

    The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR de réir Liang Zhou, Shuang Chen, Yu Zhang, Maciej Kmieciak, Yun Leng, Lihong Li, Hui‐Yi Lin, Kathryn Rizzo, Catherine I. Dumur, Andrea Ferreira‐Gonzalez, Mohamed Rahmani, Lawrence F. Povirk, Sri Lakshmi Chalasani, Allison Berger, Yun Dai, Steven Grant

    Foilsithe / Cruthaithe 2016
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  10. 10
    ATF3 and CH25H regulate effector trogocytosis and anti-tumor activities of endogenous and immunotherapeutic cytotoxic T lymphocytes

    ATF3 and CH25H regulate effector trogocytosis and anti-tumor activities of endogenous and immunotherapeutic cytotoxic T lymphocytes de réir Zhen Lu, Noreen McBrearty, Jinyun Chen, Vivek S. Tomar, Hongru Zhang, Gianluca De Rosa, Aiwen Tan, Aalim M. Weljie, Daniel P. Beiting, Zhen Miao, Subin S. George, Allison Berger, Gurpanna Saggu, J. Alan Diehl, Constantinos Koumenis, Serge Y. Fuchs

    Foilsithe / Cruthaithe 2022
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  11. 11
    Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors

    Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors de réir John Sarantopoulos, Geoffrey I. Shapiro, Roger B. Cohen, Jeffrey W. Clark, John Kauh, Glen J. Weiss, James M. Cleary, Devalingam Mahalingam, Michael D. Pickard, Hélène M. Faessel, Allison Berger, Kristine Burke, George Mulligan, Bruce J. Dezube, R. Donald Harvey

    Foilsithe / Cruthaithe 2015
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  12. 12
    Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies

    Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies de réir David C. Smith, Thea Kalebic, Jeffrey R. Infante, Lillian L. Siu, Daniel M. Sullivan, Gordana Vlahovic, John Kauh, Feng Gao, Allison Berger, Stephen Tirrell, Neeraj Gupta, Alessandra Di Bacco, Deborah Berg, Guohui Liu, Jianchang Lin, Ai-Min Hui, John A. Thompson

    Foilsithe / Cruthaithe 2015
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  13. 13
    Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma

    Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma de réir Jatin J. Shah, Andrzej Jakubowiak, Owen A. O’Connor, Robert Z. Orlowski, R. Donald Harvey, Mitchell R. Smith, Daniel Lebovic, Catherine Diefenbach, Kevin R. Kelly, Zhaowei Hua, Allison Berger, George Mulligan, Hélène M. Faessel, Stephen Tirrell, Bruce J. Dezube, Sagar Lonial

    Foilsithe / Cruthaithe 2015
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  14. 14
    Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer

    Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer de réir Erik Kupperman, Edmund C. Lee, Yueying Cao, Bret Bannerman, Michael Fitzgerald, Allison Berger, Jie Yu, Yang Yu, Paul Hales, Frank J. Bruzzese, Jane Liu, Jonathan L. Blank, Khristofer Garcia, Christopher Tsu, Lawrence R. Dick, Paul Fleming, Li Yu, Mark Manfredi, Mark Rolfe, Joe Bolen

    Foilsithe / Cruthaithe 2010
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  15. 15
    Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma

    Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma de réir Junling Zhuang, Fazal Shirazi, R. K. Singh, Isere Kuiatse, Hua Wang, Hans C. Lee, Zuzana Berkova, Allison Berger, Marc L. Hyer, Nibedita Chattopadhyay, Sakeena Syed, Judy Shi, Jie Yu, Vaishali Shinde, Stephen Tirrell, Richard J. Jones, Zhiqiang Wang, R. Eric Davis, Robert Z. Orlowski

    Foilsithe / Cruthaithe 2019
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  16. 16
    MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB–dependent lymphoma

    MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB–dependent lymphoma de réir Michael A. Milhollen, Tary Traore, Jennifer Adams-Duffy, Michael P. Thomas, Allison Berger, Lenny Dang, Lawrence R. Dick, James Garnsey, Erik Koenig, Steven Langston, Mark Manfredi, Usha Narayanan, Mark Rolfe, Louis M. Staudt, Teresa A. Soucy, Jie Yu, Julie Zhang, Joseph B. Bolen, Peter G. Smith

    Foilsithe / Cruthaithe 2010
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  17. 17
    Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease

    Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease de réir Antonio García-Gómez, Dalia Quwaider, Miriam Canavese, Enrique M. Ocio, Ze Tian, Juan F. Blanco, Allison Berger, Carlos Ortíz-de-Solórzano, Teresa Hernández‐Iglesias, Anton C. Martens, Richard W.J. Groen, Joaquín Mateo-Urdiales, Susana Fraile, Miguel Galarraga, Dharminder Chauhan, Jesús F. San Miguel, Noopur Raje, Mercedes Garayoa

    Foilsithe / Cruthaithe 2014
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  18. 18
    Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies

    Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies de réir Edmund C. Lee, Michael Fitzgerald, Bret Bannerman, Jill Donelan, Kristen Bano, Jennifer Terkelsen, Daniel P. Bradley, Ozlem Subakan, Matthew D. Silva, Ray Liu, Michael D. Pickard, Zhi Li, Olga Tayber, Ping Li, Paul Hales, Mary Carsillo, Vishala T. Neppalli, Allison Berger, Erik Kupperman, Mark Manfredi, Joseph B. Bolen, Brian Van Ness, Siegfried Janz

    Foilsithe / Cruthaithe 2011
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  19. 19
    Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy

    Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy de réir George Mulligan, David I. Lichter, Alessandra Di Bacco, Stephen J. Blakemore, Allison Berger, Erik Koenig, Hugues Bernard, William L. Trepicchio, Bin Li, Rachel Neuwirth, Nibedita Chattopadhyay, Joseph B. Bolen, Andrew J. Dorner, Helgi van de Velde, Deborah Ricci, Sundar Jagannath, James R. Berenson, Paul G. Richardson, Edward A. Stadtmauer, Robert Z. Orlowski, Sagar Lonial, Kenneth C. Anderson, Pieter Sonneveld, Jesús F. San Miguel, Dixie‐Lee Esseltine, Matthew Schu

    Foilsithe / Cruthaithe 2013
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:

Uirlisí cuardaigh: